Fig 1.
Immunohistochemical staining of SP in breast cancer tissues and positive control.
(a) Positive control (lung tissues). (b-h) Different SP expression total scores (TS) in breast cancer tissues from 0–8. (b) Score 0. (c) Score 3. (d) Score 4. (e) Score 5. (f) Score 6. (g) Score 7. (h) Score 8. Original magnification 20x.
Table 1.
Demographic and clinicopathological characteristics of 164 female patients with breast cancer.
Fig 2.
Distribution of Ki-67 expression in breast cancer cases.
(a) Number of cases in each group with different Ki-67 scores. (b) Mean Ki-67 scores in different breast cancer molecular subtypes. (c) Mean Ki-67 scores in breast cancer cases of different grades. (d) Mean Ki-67 scores in breast cancer cases of different pN stages. TNBC, triple negative breast cancer. Tukey’s post hoc multiple comparisons test was performed to identify significant differences between breast cancer subgroups.
Table 2.
Clinicopathological features of breast cancer patients in relation to Substance P (SP) expression.
Fig 3.
Distribution of substance P (SP) expression in breast cancer cases.
(a) SP expression level in different breast cancer molecular subtypes. (b) SP expression level in breast cancer cases of different TNM stages. (c) SP expression level in breast cancer cases of different pT stages. (d) SP expression level in breast cancer cases of different pN stages. TNBC, triple negative breast cancer. Bonferroni Chi-Square residual analysis was performed to identify significant differences between breast cancer subgroups. Adjusted p-values were calculated as 0.05/ntests.
Table 3.
Clinicopathological features of breast cancer patients in relation to Ki-67 expression.